Depomed finalizes breakup with Abbott, regains rights to PHN drug
This article was originally published in Scrip
Executive Summary
Depomed revealed that it had settled a dispute with Abbott over whether the latter firm was obliged to launch Gralise, Depomed's once-daily oral formulation of gabapentin.